{"id":"epoetin-theta","rwe":[{"pmid":"38320573","year":"2024","title":"Evaluation of a single Eporatio® micro-dose in urine and dried blood spots.","finding":"","journal":"Drug testing and analysis","studyType":"Clinical Study"},{"pmid":"28066881","year":"2017","title":"Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"26708119","year":"2016","title":"Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study.","finding":"","journal":"Clinical therapeutics","studyType":"Clinical Study"},{"pmid":"24656152","year":"2014","title":"Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.","finding":"","journal":"Clinical therapeutics","studyType":"Clinical Study"},{"pmid":"25780623","year":"2014","title":"Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review.","finding":"","journal":"Canadian journal of kidney health and disease","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Erythropoietin receptor","category":"target"},{"label":"EPOR","category":"gene"},{"label":"Active","category":"status"},{"label":"Anemia due to chemotherapy","category":"indication"},{"label":"Anemia of chronic renal failure","category":"indication"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EPOETIN THETA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:57:21.826199+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Epoetin Theta","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:57:30.117401+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:57:28.831811+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:57:21.894321+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPOETIN THETA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:57:29.068104+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Erythropoietin receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:57:30.117318+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108290/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:57:29.776113+00:00"}},"allNames":"eporatio","offLabel":[],"synonyms":["epoetin theta","eporatio"],"timeline":[{"date":"2009-10-29","type":"positive","source":"DrugCentral","milestone":"EMA approval"}],"approvals":[{"date":"2009-10-29","orphan":false,"company":"","regulator":"EMA"}],"brandName":"Eporatio","ecosystem":[{"indication":"Anemia due to chemotherapy","otherDrugs":[{"name":"epoetin alfa","slug":"epoetin-alfa","company":"Amgen"}],"globalPrevalence":null},{"indication":"Anemia of chronic renal failure","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Erythropoietin receptor","targets":[{"gene":"EPOR","source":"DrugCentral","target":"Erythropoietin receptor","protein":"Erythropoietin receptor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Eporatio is a small molecule that binds to the extracellular domain of the erythropoietin receptor, triggering a conformational change that activates the receptor's tyrosine kinase activity, leading to the activation of downstream signaling pathways that stimulate erythropoiesis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Epoetin_theta","title":"Epoetin theta","extract":"Epoetin theta, sold under the brand name Biopoin among others, is a form of the human hormone erythropoietin produced using recombinant DNA technology."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5007","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPOETIN%20THETA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPOETIN THETA","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Epoetin_theta","fields":["history","overview"],"source":"Wikipedia"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:03:54.385709","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:57:31.423369+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"darbepoetin alfa","drugSlug":"darbepoetin-alfa","fdaApproval":"2001-09-17","relationship":"same-target"},{"drugName":"epoetin alfa","drugSlug":"epoetin-alfa","fdaApproval":"1989-06-01","relationship":"same-target"},{"drugName":"methoxy polyethylene glycol-epoetin beta","drugSlug":"methoxy-polyethylene-glycol-epoetin-beta","fdaApproval":"2007-11-14","relationship":"same-target"},{"drugName":"peginesatide","drugSlug":"peginesatide","fdaApproval":"2012-03-27","patentExpiry":"Jun 2, 2026","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"epoetin theta","indications":{"approved":[{"name":"Anemia due to chemotherapy","source":"DrugCentral","snomedId":429564000,"regulator":"FDA"},{"name":"Anemia of chronic renal failure","source":"DrugCentral","snomedId":49708008,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"darbepoetin-alfa","brandName":"darbepoetin alfa","genericName":"darbepoetin alfa","approvalYear":"2001","relationship":"same-target"},{"drugId":"epoetin-alfa","brandName":"epoetin alfa","genericName":"epoetin alfa","approvalYear":"1989","relationship":"same-target"},{"drugId":"methoxy-polyethylene-glycol-epoetin-beta","brandName":"methoxy polyethylene glycol-epoetin beta","genericName":"methoxy polyethylene glycol-epoetin beta","approvalYear":"2007","relationship":"same-target"},{"drugId":"peginesatide","brandName":"peginesatide","genericName":"peginesatide","approvalYear":"2012","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05080049","phase":"PHASE3","title":"Erythropoietin to Improve Critical Care Patient Outcomes","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2022-01-28","conditions":["Anemia","Intensive Care"],"enrollment":42,"completionDate":"2022-12-31"}],"_emaApprovals":[{"date":"2009-10-29","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"013375","UMLSCUI":"C2746991","chemblId":"CHEMBL2108290","ChEMBL_ID":"CHEMBL2108290","DRUGBANK_ID":"DB00016","SNOMEDCT_US":"708829008","MESH_SUPPLEMENTAL_RECORD_UI":"C555712"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2024 Nov","pmid":"38320573","title":"Evaluation of a single Eporatio® micro-dose in urine and dried blood spots.","journal":"Drug testing and analysis"},{"date":"2017 Jan 9","pmid":"28066881","title":"Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients.","journal":"The Cochrane database of systematic reviews"},{"date":"2016 Feb","pmid":"26708119","title":"Cardiovascular Morbidity and Pure Red Cell Aplasia Associated With Epoetin Theta Therapy in Patients With Chronic Kidney Disease: A Prospective, Noninterventional, Multicenter Cohort Study.","journal":"Clinical therapeutics"},{"date":"2014 Apr 1","pmid":"24656152","title":"Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.","journal":"Clinical therapeutics"},{"date":"2014","pmid":"25780623","title":"Efficacy and safety data of subsequent entry biologics pertinent to nephrology practice: a systematic review.","journal":"Canadian journal of kidney health and disease"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Recombinant protein","firstApprovalDate":"2009","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:57:31.423369+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}